La Chaux-de-Fonds, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor in hematological malignancies and solid tumors

--- Three preclinical poster presentations highlight the potential of RP4010 alone and in combination with approved drugs for treating hematological malignancies and solid tumors

--- A multi-center Phase I/IB dose-escalation trial evaluating the safety and efficacy of RP4010, a CRAC channel inhibitor in patients with relapsed or refractory Non-Hodgkin Lymphoma (NHL) is currently ongoing in USA (ClinicalTrials.gov Identifier: NCT03119467)

About RP4010:

RP4010 is a novel first-in-class oral small molecule inhibitor of calcium release activated calcium (CRAC) channel pathway with demonstrated preclinical activity in a broad range of cancers.   Aberrant CRAC channel activity has been linked to various autoimmune disorders and certain cancers via the NFAT pathway.  In addition, the blockage of store-operated calcium entry (SOCE) by a CRAC channel inhibitor could suppress tumor growth through a number of mechanisms, including the inhibition of calcium-dependent activation of Akt/NF-kB and ERK 1/2 pathways.

Details of the poster presentations:

-- Poster Title:  Antitumor activity of RP4010, a novel small-molecule inhibitor of the calcium release-activated calcium (CRAC) channel pathway

• Session Title:                      Poster Session B
• Session Category:               Therapeutic Agents: Other Topics
• Session Date & Time:          Sunday, October 29, 2017; 12:30 PM – 4:00 PM
• Location:                            Hall E, Pennsylvania Convention Center
• Poster Board Number:         127

-- Poster Title:  Efficacy of RP4010, a calcium release-activated calcium (CRAC) inhibitor, in preclinical models of DLBCL

• Session Title:                      Poster Session B
• Session Category:               Therapeutic Agents: Other Topics
• Session Date & Time:          Sunday, October 29, 2017; 12:30 PM – 4:00 PM
• Location:                            Hall E, Pennsylvania Convention Center
• Poster Board Number:         128

-- Poster Title:  Targeting Orai1-mediated store-operated Ca²⁺ entry by a novel compound RP4010 for antiproliferative activity against Esophagus Squamous Cell Carcinoma

• Session Title:                      Poster Session B
• Session Category:               New Molecular Targets
• Session Date & Time:          Sunday, October 29, 2017; 12:30 PM – 4:00 PM
• Location:                            Hall E, Pennsylvania Convention Center
• Poster Board Number:         62

About Rhizen Pharmaceuticals S.A.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders.  Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways.  Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland.  For additional information, please visit Rhizen’s website, www.rhizen.com.

Contact:         
Kumar V. Penmetsa, Ph.D.
Executive Vice President, Corporate Development
Rhizen Pharmaceuticals S.A.
Telephone:  +1-267-207-5707
Email:  kvp@rhizen.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.